CytomX Therapeutics Profile

USD 0.23  1.12%
19.79Last Month High 21.06 
20.66Trading Day  High 21.08 

Sale by Debanjan Ray of 2500 shares of CytomX Therapeutics

CytomX Therapeutics Inc insider trading alert for sale of common stock by Debanjan Ray, Chief Financial Officer, on December 5, 2017. This event was filed by Cytomx Therapeutics Inc with SEC on 2017-12-05. Statement of changes in beneficial ownership - SEC Form 4. Debanjan Ray is currently serves as cfo, principal financial and accounting officer of CytomX Therapeutics Inc [view details]   

CytomX Therapeutics Summary

CytomX Therapeutics Inc (CTMX) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 63 people. CytomX Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Small-Cap' category with current market capitalization of 766.44 M. CytomX Therapeutics Inc has 38.41 M outstanding shares of which 1.18 M shares are currently shorted by private and institutional investors with about 5.05 trading days to cover. CytomX Therapeutics currently holds about 331.28 M in cash with 150.31 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.11.
Check CytomX Therapeutics Probability Of Bankruptcy

Ownership Allocation (%)

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Fmr LlcCommon Shares5.5 M100.5 M
Bvf IncCommon Shares2.2 M40.5 M
View CytomX Therapeutics Diagnostics

Selected CytomX Therapeutics Inc Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

CytomX Therapeutics Against Markets

Current Ratings  

CytomX Therapeutics 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
Chance of
< 44% 
CytomX Therapeutics, Inc. operates as an oncologyfocused biopharmaceutical company in the United States. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameCytomX Therapeutics Inc
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock Stocks Directory
RegionNorth America
Business AddressCytomX Therapeutics, Inc.South San Francisco, CA
CIK Number01501989.0
IndustryPharmaceutical Products
Contact Number650 515 3185
CurrencyUSD - US Dollar


CytomX Therapeutics Analyst Recommendations
Target PriceAdvice# of Analysts
CytomX Therapeutics Inc current and past analyst recommendations published by number of research institutions as well as average analyst consensus
CytomX Therapeutics Analyst Advice  


Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  


CytomX Therapeutics Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.45March 6, 2017
CytomX Therapeutics Inc normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate